 | | | | Novavax Inc on Monday cut its full-year revenue forecast by half, as the vaccine maker battles low demand for its COVID-19 shot, sending its shares down 32% in extended trading. | | | | | | The package, called the Inflation Reduction Act, is a dramatically scaled-back version of a prior bill that was blocked by maverick Senate Democrats Joe Manchin and Kyrsten Sinema as too expensive. | | | | | | Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment. | | | | | | Brazilian pharmaceutical company Biolab has bought Canadian healthcare business Exzell Pharma, the company said in a statement on Monday. | | | | | | Italy opened its vaccination campaign against monkeypox on Monday, as case numbers have increased at a time when health authorities are reporting vaccine shortages worldwide. | | | | | | The Chinese autonomous region of Tibet, which had barely reported COVID patients for more than two years, is facing a spate of new infections, forcing it to impose various restriction in its second largest city. | | | | | | BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October, which will help spur demand in the fourth quarter, the German biotech firm said on Monday as it reaffirmed its vaccine-revenue forecast for the year. | | | | | | Hong Kong will shorten the COVID-19 hotel quarantine period for all arrivals to three days from seven, taking another step to gradually unwind stringent pandemic rules that have isolated the Asian financial hub. | | | | | | With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot. | | | | | | Democrats hope its passage, ahead of an August recess, will help the party's House and Senate candidates in the November midterm elections at a time when President Biden is suffering from anemic public approval ratings amid high inflation. | | | | | |
